NKR 2 - Celyad

Drug Profile

NKR 2 - Celyad

Alternative Names: CAR NKG2D; CAR-T NKR-2; CM-CS-1; CYAD-01; NKR 2 T-cell; NKR-2; NKR-2 T-cell immunotherapy; NKR-T cells

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dartmouth College
  • Developer Celyad; Dana-Farber Cancer Institute
  • Class Antineoplastics; CAR-T cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Angiogenesis inhibitors; Cytotoxic T lymphocyte stimulants; Immunostimulants; NK cell lectin-like receptor subfamily K modulators; Regulatory T lymphocyte inhibitors; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma; Solid tumours
  • Phase I Colorectal cancer

Most Recent Events

  • 03 Oct 2017 Adverse events data from the phase I/II THINK trial in Solid tumours released by Celyad
  • 20 Jul 2017 Phase-I clinical trials in Colorectal cancer (Late-stage disease) in Belgium (IV)
  • 19 Jun 2017 Efficacy data from the phase I/II THINK trial in Solid tumours released by Celyad
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top